On December 10, 2021, Eli Lilly and Company and Regor Therapeutics Group entered into a multi-year research collaboration and licensing agreement to discover, develop, and commercialize novel therapies for metabolic disorders. Wilson Sonsini Goodrich & Rosati represented Regor Therapeutics Group in the transaction.

Under the terms of the agreement, Lilly will have a license to select Regor intellectual property with an option to extend the license. Lilly will be responsible for clinical development, manufacturing, and commercialization worldwide, except for People's Republic of China, Macau, Hong Kong, and Taiwan, where Regor will maintain these rights and responsibilities. The agreement will allow each company the opportunity to fully leverage both parties' existing compounds and technologies globally to maximize patient treatment choice.

Regor will receive an upfront payment of up to $50 million, which partially includes an equity investment by Lilly in Regor, subject to the parties entering into standard equity agreements. The company is also eligible to receive up to $1.5 billion in potential payments based on the achievement of prespecified preclinical, clinical development, and commercial milestones, as well as tiered royalties from low-single to low-double digits on sales resulting from the agreement.

The Wilson Sonsini team that advised Regor was led by technology transactions partner John Wehrli and included John Krocak and Sai Upadhyayula.

For more information, please see the press release.